An Aggrephagy-Related LncRNA Signature for the Prognosis of Pancreatic Adenocarcinoma

Xueyuan Huang; Hao Chi; Siqi Gou; Xiyuan Guo; Lin Li; Gaoge Peng; Jinhao Zhang; Jiayu Xu; Siji Nian; Qing Yuan

doi:10.3390/genes14010124

An Aggrephagy-Related LncRNA Signature for the Prognosis of Pancreatic Adenocarcinoma

Genes (Basel). 2023 Jan 2;14(1):124. doi: 10.3390/genes14010124.

Authors

Xueyuan Huang^{1

2}, Hao Chi², Siqi Gou², Xiyuan Guo¹, Lin Li¹, Gaoge Peng², Jinhao Zhang³, Jiayu Xu⁴, Siji Nian¹, Qing Yuan¹

Affiliations

¹ Immune Mechanism and Therapy of Major Diseases of Luzhou Key Laboratory, Public Center of Experimental Technology, School of Basic Medical Sciences, Southwest Medical University, Luzhou 646000, China.
² Clinical Medical College, Southwest Medical University, Luzhou 646000, China.
³ School of Stomatology, Southwest Medical University, Luzhou 646000, China.
⁴ Statistics Department, School of Science, Minzu University of China, Beijing 100081, China.

Abstract

Pancreatic adenocarcinoma (PAAD) is a common, highly malignant, and aggressive gastrointestinal tumor. The conventional treatment of PAAD shows poor results, and patients have poor prognosis. The synthesis and degradation of proteins are essential for the occurrence and development of tumors. Aggrephagy is a type of autophagy that selectively degrades aggregated proteins. It decreases the formation of aggregates by degrading proteins, thus reducing the harm to cells. By breaking down proteins, it decreases the formation of aggregates; thus, minimizing damage to cells. For evaluating the response to immunotherapy and prognosis in PAAD patients, in this study, we developed a reliable signature based on aggrephagy-related genes (ARGs). We obtained 298 AGGLncRNAs. Based on the results of one-way Cox and LASSO analyses, the lncRNA signature was constructed. In the risk model, the prognosis of patients in the low-risk group was noticeably better than that of the patients in the high-risk group. Additionally, the ROC curves and nomograms validated the capacity of the risk model to predict the prognosis of PAAD. The patients in the low-risk and high-risk groups showed considerable variations in functional enrichment and immunological analysis. Regarding drug sensitivity, the low-risk and high-risk groups had different half-maximal inhibitory concentrations (IC50).

Keywords: LncRNA; PAAD; aggrephagy; immunotherapy; prognostic signature.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adenocarcinoma* / genetics
Humans
Macroautophagy
Pancreatic Neoplasms* / genetics
Prognosis
RNA, Long Noncoding* / genetics

Substances

RNA, Long Noncoding

Grants and funding

This work was supported by the project of the Science and Technology Department of Sichuan Province (2022NSFSC0699), the joint project of Sichuan University and Luzhou industrial research Institute (2020CDLZ-24), the joint innovation project of Sichuan Science and Technology plan (2022YFS0636-B3, 2022YFS0608-B1), and the project of Southwest Medical University (2022CXY06).